GlassScriptPhysician profile
Karmen E Goosey
NPI 1609860022
$10,505.63
in general payments reported to CMS, 2019-2025
38 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,468 · 2022: $1,639 · 2023: $2,202 · 2024: $2,361 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,317 · Education: $81.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,317.26 |
| Education | $81.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,505.45 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,568.17 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $927.64 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.61 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $510.60 | 2021-2025 | |
| Lilly USA, LLC | $498.38 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $389.82 | 2021-2025 | Repatha, Otezla, Otezla |
| Neurocrine Biosciences, INC. | $330.59 | 2022-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $280.94 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $268.81 | 2023-2024 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $263.38 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $257.29 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $252.80 | 2024-2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $243.30 | 2021-2025 | Belsomra, Vaxneuvance, Enflonsia |
| Bayer Healthcare Pharmaceuticals INC. | $177.07 | 2023-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karmen Goosey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.